Correlation of CALL score with disease progression in COVID-19 patients

Preetham Beguru Subramanya, Naazim Javed Khan, M. Mahendra, Imran Khan, Nisha Ravikumar


Background: Many prognostic models have been introduced to predict the disease progression in an individual with COVID-19, CALL score is one among them. The objective of the study was to evaluate the role of comorbidity, high age, low lymphocyte count, high lactate dehydrogenase (CALL) score in predicting disease progression and mortality in COVID 19 patients.

Methods: Total 105 patients were divided into - stable group (CALL≤6) and progressive group (CALL>6), Chi- square test and ROC analysis is applied to predict the outcomes like oxygen requirement, ICU requirement (high flow nasal oxygen), invasive ventilation requirement, increase in respiratory rate ≥30 Cpm and death/recovery with CALL score in both the groups.

Results: ROC analysis was done to predict outcome based on CALL score in both groups which showed sensitivity 100% (91.6% to 100%), specificity of 8.2% (2.7 to 18.1%), PPV – 44% (42.16 to 45.86%) and NPV – 100%.

Conclusions: Using the CALL score model with cut off of 6 points, clinicians can predict the progression risk in terms of higher respiratory rate ≥30 cpm, oxygen requirement, requiring ICU, death/ recovery. 


CALL score, COVID-19, Disease progression

Full Text:



Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.

World Health Organization, Clinical management of COVID-19, Interim guidance 2020. Available at: clinical-management-of-COVID-19. Accessed on 27 May 2020.

Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. Ann Intensive Care. 2020;10:33.

Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.

Chen N, Zhou M, Dong X. Epidemiological and clinical char- acteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513.Chau AS, Weber AG, Maria NI, et al. The longitudinal immune re- sponse to coronavirus disease 2019: chasing the cytokine storm. Arthritis Rheumatol. 2021;73:23-35.

Clemente GMM, Huertas HJ, Fernandez A, Munoz C, Rodriguez EAI, Martinez L et al. Assessment of risk scores in Covid‐19. International Journal of Clinical Practice. 2021 Dec;75(12):e13705.

Ji D, Zhang D, Xu J. Prediction for Progression Risk in Patients With COVID-19 Pneumonia: the CALL Score. Clin Infect Dis. 2020;71:1393-9.

Wynants L, Van Calster B, Collins GS. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal. BMJ. 2020;369:m1328.

Poco PCE, Aliberti MJR, Dias MB. Divergent: age, frailty, and atypical presentations of COVID-19 in hospitalized patients. J Gerontol A Biol Sci Med Sci. 2021;76:e46-51.

Josa-Laorden C, Crestelo-Vieitez A, Andreu GMDM. Gender- based differences by age range in patients hospitalized with COVID-19: a Spanish Observational Cohort Study. J Clin Med. 2021;10:899.

Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021;47:100761.

Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus dis- ease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58:1021-8.

Kamran SM, Moeed HA, Naseem A, Hussain M, Fazal Sr I, Saeed F et al. CALL score and RAS score as predictive models for coronavirus disease 2019. Cureus. 2020;12(11).

Kopel J, Perisetti A, Roghani A, Aziz M, Gajendran M, Goyal H. Racial and gender-based differences in COVID-19. Front Public Health. 2020;8:418.